Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536091 | 1.00 | L3MBTL1 (0.43) | L3MBTL1NAMPTMEN1KMT2APOLB | |
| SCHEMBL1536041 | 0.90 | L3MBTL1 (0.42) | L3MBTL1NAMPTMEN1KMT2APOLB | |
| SCHEMBL29875257 | 0.87 | PIK3C3 (0.45) | L3MBTL1MEN1KMT2ANOD1PIK3C3 | |
| SCHEMBL18740449 | 0.87 | PIK3C3 (0.45) | L3MBTL1MEN1KMT2ANOD1PIK3C3 | |
| SCHEMBL4348950 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2APOLBNOD1 | |
| SCHEMBL13579601 | 0.85 | L3MBTL1 (0.41) | L3MBTL1NAMPTMEN1KMT2APOLB | |
| SCHEMBL13579548 | 0.85 | GSK3B (0.39) | NAMPTMEN1KMT2ARORCGSK3B | |
| SCHEMBL31497538 | 0.83 | NOD1 (0.40) | L3MBTL1NAMPTMEN1KMT2APOLB | |
| SCHEMBL31137773 | 0.83 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2APOLBNOD1 | |
| SCHEMBL12389611 | 0.83 | CA12 (0.42) | L3MBTL1NAMPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | CURIA SPAIN, S.A.U. (ES) | 2026-02-17 | — | — | US | disclosed |
| CN-117603117-B | Preparation method of chiral 3- (2-haloacetyl) -4-ethylpyrrolidine | 江苏海洋大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-118724783-A | Preparation of Wupati method for preparing nylon intermediate | 尚科生物医药（上海）有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-117603117-A | Preparation method of chiral 3- (2-haloacetyl) -4-ethylpyrrolidine | 江苏海洋大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-117304194-B | Synthesis method of lapatinib | 中节能万润股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117304194-A | Synthesis method of lapatinib | 中节能万润股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116396299-B | Method for preparing Wu Pa tenib intermediate | 和鼎（南京）医药技术有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116396299-A | Method for preparing Wu Pa tenib intermediate | 和鼎（南京）医药技术有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN, S.A.U. (ES) | 2023-05-04 | — | — | US | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-110117285-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4077276-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | Curia Spain S.A.U. (ES) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | L3MBTL1 1190/4885NAMPT 2065/4885MEN1 348/4885 |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CDK19, CDK11B, CDK9 | L3MBTL1 4201/4885NAMPT 1229/4885MEN1 2330/4885 |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | JAK1, JAK3, MET | L3MBTL1 952/4885NAMPT 1781/4885MEN1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.